Journal
ADVANCES IN CHRONIC KIDNEY DISEASE
Volume 17, Issue 5, Pages 439-449Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2010.06.003
Keywords
Diabetes mellitus; Chronic kidney disease; End stage renal disease; Incretins; Glucagon like peptide-1
Categories
Ask authors/readers for more resources
Type 2 diabetes mellitus (T2DM) with concomitant CKD is an emerging clinical and public health problem reaching epidemic proportions in the United States. Achieving and maintaining glycemic targets in clinical practice are significant challenges in majority of the patients with T2DM and CKD, and this has created significant barriers for clinicians managing these patients. Commonly used antihyperglycemic agents are either contraindicated or lack efficacy and safety information in this population. Recently, 2 distinct classes of agents that augment incretin hormone action have been added to the therapeutic armamentarium targeting hyperglycemia. This review will discuss the literature examining the efficacy and safety of incretin-based therapies in T2DM and the available evidence for their use in CKD. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available